Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

122.26 +0.40 (+0.33%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

USDA Unveils $100 Million 'Grand Challenge' to Thwart Flesh-Eating Screwworm as Threat Reaches U.S. Border

February 05, 2026

In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New...

Via MarketMinute

Topics Death Economy

AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗

February 04, 2026

Via Chartmill

Topics Artificial Intelligence

How Merck Is Preparing For The Patent Cliff Of Its Blockbuster Cancer Drug Keytruda ↗

February 04, 2026

Scotiabank lifted its Merck target to $136 and kept an ‘Outperform’ rating, implying a 17% upside.

Via Stocktwits

Topics Earnings Intellectual Property

MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance

February 04, 2026

Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue...

Via StockStory

Merck & Co. Inc. (NYSE:MRK) Beats Q4 Estimates but 2026 Outlook Cautions Investors ↗

February 03, 2026

Via Chartmill

Technical Breakout Setup for Merck & Co. Inc. (NYSE:MRK) ↗

January 31, 2026

Via Chartmill

Merck (MRK) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Merck (MRK) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates

February 03, 2026

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue...

Via StockStory

Topics Earnings

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

February 03, 2026

From Merck & Co., Inc.

Via Business Wire

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock ↗

January 24, 2026

Via Chartmill

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Merck (MRK) Q4 Earnings Report Preview: What To Look For

February 01, 2026

Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Tuesday before the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

This genomics stock appears to be at an inflection point.

Via The Motley Fool

Topics Earnings

2 Cash-Producing Stocks to Target This Week and 1 We Ignore

January 28, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

This Stock Is Already Up 58% This Year. Is It a Buy? ↗

January 28, 2026

This forgotten pandemic stock hasn't said its last word.

Via The Motley Fool

Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility

January 28, 2026

As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and...

Via MarketMinute

Topics Economy Government World Trade

The $4 Billion Avatar: How Synthesia is Defining the Era of Agentic Enterprise Media

January 28, 2026

In a landmark moment for the synthetic media landscape, London-based AI powerhouse Synthesia has reached a staggering $4 billion valuation following a $200 million Series E funding round. Announced on...

Via TokenRing AI

Topics Artificial Intelligence

FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency

January 28, 2026

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial...

Via TokenRing AI

Topics Artificial Intelligence Economy

Merck Announces Second-Quarter 2026 Dividend

January 27, 2026

From Merck & Co., Inc.

Via Business Wire

2 Pharmaceutical Stocks Set to Rebound in 2026 ↗

January 27, 2026

There might be massive upside ahead for these drugmakers.

Via The Motley Fool

Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗

January 26, 2026

It doesn't look like the company will end up in the arms of an acquirer soon, after all.

Via The Motley Fool

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse ↗

January 26, 2026

Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement.

Via Benzinga

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗

January 26, 2026

Via Stocktwits

Topics Economy Stocks

Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗

January 26, 2026

Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.”

Via Stocktwits

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

2 Dirt Cheap Stocks to Buy With $200 Right Now ↗

January 24, 2026

These healthcare leaders seem attractive right now.

Via The Motley Fool

Topics Artificial Intelligence

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

January 23, 2026

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.